{"protocolSection":{"identificationModule":{"nctId":"NCT06980649","orgStudyIdInfo":{"id":"BHV1300-202"},"organization":{"fullName":"Biohaven Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Study of BHV-1300 in Graves' Disease","officialTitle":"An Open-Label Biomarker Study of BHV-1300 in Graves' Disease"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-08-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-05-12","studyFirstSubmitQcDate":"2025-05-12","studyFirstPostDateStruct":{"date":"2025-05-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-21","lastUpdatePostDateStruct":{"date":"2025-11-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biohaven Therapeutics Ltd.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers."},"conditionsModule":{"conditions":["Graves Disease"],"keywords":["Autoimmune thyroid disease","hyperthyroidism","anti thyroid drug","thyroid disease","autoimmune diseases","endocrine system diseases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":15,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BHV-1300","type":"EXPERIMENTAL","interventionNames":["Drug: BHV-1300"]}],"interventions":[{"type":"DRUG","name":"BHV-1300","description":"BHV-1300 is delivered subcutaneously (SC)","armGroupLabels":["BHV-1300"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths","description":"To assess the safety and tolerability of BHV-1300. This objective will be measured by assessing the number of unique subjects with SAEs, AEs leading to discontinuation or deaths that are observed during the Open-label Treatment Phase (up to 12 weeks).","timeFrame":"Baseline to Week 12"},{"measure":"Number of participants with Grade 3-4 (CTCAE/DAIDS) treatment-emergent laboratory abnormalities","description":"To assess the safety and tolerability of BHV-1300. This objective will be measured by assessing the number of unique subjects with Grade 3 or 4 treatment-emergent laboratory abnormalities.","timeFrame":"Baseline to Week 12"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1\\. Participants must have serologically confirmed Graves' Disease.\n\nKey Exclusion Criteria:\n\n1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.\n2. History of treatment with radioactive iodine or thyroid surgery.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Chief Medical Officer","role":"CONTACT","phone":"203-404-0410","email":"clinicaltrials@biohavenpharma.com"}],"locations":[{"facility":"Site-103","status":"RECRUITING","city":"South Gate","state":"California","zip":"90280","country":"United States","geoPoint":{"lat":33.95474,"lon":-118.21202}},{"facility":"Site-100","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33126","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Site-104","status":"RECRUITING","city":"Columbus","state":"Georgia","zip":"31904","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Site-106","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77054","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Site-101","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77095","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Site-105","status":"RECRUITING","city":"Shavano Park","state":"Texas","zip":"78231","country":"United States","geoPoint":{"lat":29.58495,"lon":-98.55252}},{"facility":"Site-004","status":"RECRUITING","city":"Fitzroy","zip":"3065","country":"Australia","geoPoint":{"lat":-37.79839,"lon":144.97833}},{"facility":"Site-001","status":"RECRUITING","city":"Kotara","zip":"2289","country":"Australia","geoPoint":{"lat":-32.94282,"lon":151.69585}},{"facility":"Site-003","status":"RECRUITING","city":"Melbourne","zip":"3128","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Site-008","status":"RECRUITING","city":"Parkville","zip":"3050","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"Site-006","status":"RECRUITING","city":"St Leonards","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Site-002","status":"RECRUITING","city":"Torquay","zip":"3228","country":"Australia","geoPoint":{"lat":-38.33085,"lon":144.32638}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D006111","term":"Graves Disease"},{"id":"D006980","term":"Hyperthyroidism"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}],"ancestors":[{"id":"D005094","term":"Exophthalmos"},{"id":"D009916","term":"Orbital Diseases"},{"id":"D005128","term":"Eye Diseases"},{"id":"D006042","term":"Goiter"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false}